Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Verani

Showing results (251-260 of 259) with videos related to

Pageof 26
Sort By:
You have reached the last page of results.This site can display upto 259 results.
JAMA|November 4, 2021
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease SeverityMark W Tenforde, Wesley H Self, Katherine Adams, et al.
The Journal of Infectious Diseases|December 21, 2021
Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021Nathaniel M Lewis, Eric A Naioti, Wesley H Self, et al.
Medrxiv : the Preprint Server for Health Sciences|February 16, 2022
Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational StudyAdam S Lauring, Mark W Tenforde, James D Chappell, et al.
BMJ (Clinical Research Ed.)|March 10, 2022
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational studyAdam S Lauring, Mark W Tenforde, James D Chappell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 6, 2021
Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United StatesMark W Tenforde, Manish M Patel, Adit A Ginde, et al.
The Lancet Regional Health. Southeast Asia|June 15, 2026
Pneumococcal meningitis among hospitalised children after introduction of pneumococcal conjugate vaccine in India: a sentinel hospital surveillance (2019-2022)Girish Kumar Chethrapilly Purushothaman, Prabu Rajkumar, Boopathi Kangusamy, et al.
MMWR. Morbidity and Mortality Weekly Report|September 23, 2021
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021Wesley H Self, Mark W Tenforde, Jillian P Rhoads, et al.
The Lancet. Infectious Diseases|December 20, 2024
Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysisMaria Garcia Quesada, Meagan E Peterson, Julia C Bennett, et al.
Plos One|September 3, 2020
Enhanced contact investigations for nine early travel-related cases of SARS-CoV-2 in the United StatesRachel M Burke, Sharon Balter, Emily Barnes, et al.
Pageof 26

Showing results (251-260 of 259) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 259 results.
JAMA|November 4, 2021
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease SeverityMark W Tenforde, Wesley H Self, Katherine Adams, et al.
The Journal of Infectious Diseases|December 21, 2021
Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021Nathaniel M Lewis, Eric A Naioti, Wesley H Self, et al.
Medrxiv : the Preprint Server for Health Sciences|February 16, 2022
Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational StudyAdam S Lauring, Mark W Tenforde, James D Chappell, et al.
BMJ (Clinical Research Ed.)|March 10, 2022
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational studyAdam S Lauring, Mark W Tenforde, James D Chappell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 6, 2021
Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United StatesMark W Tenforde, Manish M Patel, Adit A Ginde, et al.
The Lancet Regional Health. Southeast Asia|June 15, 2026
Pneumococcal meningitis among hospitalised children after introduction of pneumococcal conjugate vaccine in India: a sentinel hospital surveillance (2019-2022)Girish Kumar Chethrapilly Purushothaman, Prabu Rajkumar, Boopathi Kangusamy, et al.
MMWR. Morbidity and Mortality Weekly Report|September 23, 2021
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021Wesley H Self, Mark W Tenforde, Jillian P Rhoads, et al.
The Lancet. Infectious Diseases|December 20, 2024
Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysisMaria Garcia Quesada, Meagan E Peterson, Julia C Bennett, et al.
Plos One|September 3, 2020
Enhanced contact investigations for nine early travel-related cases of SARS-CoV-2 in the United StatesRachel M Burke, Sharon Balter, Emily Barnes, et al.
Pageof 26